The pharma industry on the whole is getting a boost from tax reform, but some will reap far more savings than others. And some will actually have to pay more. Here's our report card.Original Article
Who won and who lost in tax reform? AbbVie, of course, but Regeneron, Roche, AstraZeneca and more
